Charles Paulding joined Regeneron in 2013 and is currently leading the pharmacogenomics group at the Regeneron Genetics Center. His team is responsible for developing and implementing pharmacogenomic strategies for a wide range of clinical development programs at Regeneron. Charles received his BA in biology from Tufts University and his Ph.D. in genetics from Harvard University (Biological and Biomedical Sciences Program) while working in the laboratory of Dr. Daniel Haber at the Massachusetts General Hospital. Prior to joining Regeneron, Charles worked at Millennium Pharmaceuticals in the translational medicine group, and also at Novartis as head of the pharmacogenetic analysis group. While at Novartis Charles led a group that performed analysis on a range of pharmacogenetic projects across a number of therapeutic areas.
Polygenic (based on multiple genes/DNA variants) predictions for disease risk and drug response are at the forefront of recent regulatory challenges in precision medicine. Challenges in deployment range from their increased complexity, their clinical actionability, and ethical challenges when a large portion of the input data come from biased subpopulations.